A M Lincoff

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results
    S G Ellis
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 33:1278-85. 1999
  2. ncbi request reprint beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2685-8. 2001
  3. ncbi request reprint Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model
    Zhongmin Zhou
    Department of Cardiology, The Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Atherosclerosis 161:153-9. 2002
  4. ncbi request reprint Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile
    Dean J Kereiakes
    Lindner Center for Research and Education and Ohio Heart Health Center, Cincinnati, Ohio, USA
    Am J Cardiol 90:628-30. 2002
  5. ncbi request reprint Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade
    A Michael Lincoff
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 107:1556-9. 2003
  6. doi request reprint Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial
    A Michael Lincoff
    Cleveland Clinic Coordinating Center for Clinical Research C5Research, Cleveland, OH Electronic address
    Am Heart J 166:429-34. 2013
  7. ncbi request reprint Glycoprotein IIb/IIIa inhibitors
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:11S-16S. 2004
  8. doi request reprint Safety profile and bleeding risk of ticagrelor compared with clopidogrel
    Christopher H May
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue J2 3, Cleveland, OH 44195, USA
    Expert Opin Drug Saf 11:959-67. 2012
  9. ncbi request reprint Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 288:2130-5. 2002
  10. ncbi request reprint Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 289:853-63. 2003

Collaborators

Detail Information

Publications118 found, 100 shown here

  1. ncbi request reprint Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results
    S G Ellis
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 33:1278-85. 1999
    ..We sought to evaluate methodologies to compare physician-related long-term patient outcomes appropriately...
  2. ncbi request reprint beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2685-8. 2001
    ..The cogency of such a conclusion is dependent on the ability to risk-adjust for the multiple differences in patients treated with and without BBs...
  3. ncbi request reprint Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model
    Zhongmin Zhou
    Department of Cardiology, The Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Atherosclerosis 161:153-9. 2002
    ..Anti-TNF-alpha treatment was sufficient to neutralize tissue TNF-alpha activity, reduce inflammation, but did not inhibit neointimal formation following balloon angioplasty in a rabbit atherosclerotic model...
  4. ncbi request reprint Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile
    Dean J Kereiakes
    Lindner Center for Research and Education and Ohio Heart Health Center, Cincinnati, Ohio, USA
    Am J Cardiol 90:628-30. 2002
  5. ncbi request reprint Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade
    A Michael Lincoff
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 107:1556-9. 2003
  6. doi request reprint Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial
    A Michael Lincoff
    Cleveland Clinic Coordinating Center for Clinical Research C5Research, Cleveland, OH Electronic address
    Am Heart J 166:429-34. 2013
    ..The AleCardio trial examines whether the addition of aleglitazar to standard medical therapy reduces the risk of cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome...
  7. ncbi request reprint Glycoprotein IIb/IIIa inhibitors
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:11S-16S. 2004
    ..The role of glycoprotein (GP) IIb/IIIa inhibitors in interventional cardiology continues to evolve. This review focuses on contemporary research to evaluate the appropriate context for the use of GP IIb/IIIa inhibitors...
  8. doi request reprint Safety profile and bleeding risk of ticagrelor compared with clopidogrel
    Christopher H May
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue J2 3, Cleveland, OH 44195, USA
    Expert Opin Drug Saf 11:959-67. 2012
    ..Its major safety concern, as with the other ADP blockers, is bleeding. Other common adverse effects of ticagrelor such as dyspnea and ventricular pauses appear to be mild and self-limited...
  9. ncbi request reprint Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 288:2130-5. 2002
    ..Rates of nonfatal ischemic complications were significantly diminished...
  10. ncbi request reprint Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 289:853-63. 2003
    ....
  11. ncbi request reprint Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)
    A Michael Lincoff
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 93:1092-6. 2004
    ..52). This trial represents the largest prospective dataset of bivalirudin administered concomitantly with planned GP IIb/IIIa blockade and provides evidence of the safety and efficacy of this combined antithrombotic approach...
  12. ncbi request reprint Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
    A M Lincoff
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Circulation 104:163-7. 2001
    ..001); and the rise in tumor necrosis factor-alpha levels was 100% less with abciximab therapy (P=0.112). By 4 weeks, most marker levels had returned to baseline, with no significant differences between placebo and abciximab groups...
  13. ncbi request reprint Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 292:696-703. 2004
    ....
  14. doi request reprint Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 1:639-48. 2008
    ....
  15. ncbi request reprint Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA
    Am Heart J 143:847-53. 2002
    ..This agent has not yet been tested with stenting or in combination with platelet glycoprotein IIb/IIIa antagonists...
  16. ncbi request reprint Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    JAMA 298:1180-8. 2007
    ..Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence is mixed regarding the influence of medications of this class on cardiovascular outcomes...
  17. ncbi request reprint Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
    J G Peterson
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 87:532-6. 2001
    ..31, 95% CI 0.10 to 0.93, p = 0.04). Thus, the apparent positive impact of heparin on the benefits of eptifibatide therapy was largely due to confounding and bias...
  18. ncbi request reprint Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy
    Jacqueline Saw
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 44:1194-9. 2004
    ..The purpose of this study was to assess if clopidogrel pretreatment affects the relative efficacy of bivalirudin versus heparin with glycoprotein (GP) IIb/IIIa blockade for percutaneous coronary interventions (PCI)...
  19. ncbi request reprint Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials
    D P Chew
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 103:961-6. 2001
    ....
  20. ncbi request reprint Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial
    Matthews Chacko
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:1032.e1-7. 2006
    ..The REPLACE-2 trial demonstrated that bivalirudin with provisional glycoprotein IIb/IIIa (GpIIb-IIIa) blockade is noninferior to heparin with planned GpIIb-IIIa blockade during PCI, with regard to ischemic and bleeding end points...
  21. ncbi request reprint Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial
    Vivek Rajagopal
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:149-54. 2006
    ..Therefore, we sought to determine if bivalirudin has similar efficacy in ACS patients as compared with "stable" patients in the REPLACE-2 trial...
  22. ncbi request reprint Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
    ....
  23. ncbi request reprint Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
    A Michael Lincoff
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am Heart J 146:S23-30. 2003
    ..Several new anticoagulants have emerged in recent years and have been studied extensively in patients with unstable coronary syndromes and in the percutaneous coronary intervention setting...
  24. ncbi request reprint Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutan
    J Emilio Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:157-63. 2006
    ..Provisional drug was used in 374 (6%) of the 6010 patients. We sought to analyze the predictors for provisional drug use and to assess the outcomes in this cohort...
  25. ncbi request reprint Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial
    Hitinder S Gurm
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 43:542-8. 2004
    ....
  26. ncbi request reprint Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, San Antonio, Texas, USA
    Circulation 103:2572-8. 2001
    ..The optimal level of platelet inhibition with a glycoprotein (GP) IIb/IIIa antagonist necessary to minimize thrombotic complications in patients undergoing a percutaneous coronary intervention (PCI) is currently unknown...
  27. ncbi request reprint Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Out
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 32:1619-23. 1998
    ....
  28. ncbi request reprint Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]
    M A Robbins
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 84:1350-3, A8. 1999
    ....
  29. doi request reprint The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V
    Arman T Askari
    Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA
    Am Heart J 158:238-43. 2009
    ..Emerging data suggest that some of the benefit of renin-angiotensin-aldosterone system (RAAS) antagonism may be derived from a reduction in the incidence of these arrhythmias in the setting of acute myocardial infarction...
  30. ncbi request reprint Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention
    Jason O Robertson
    The Department of Cardiovascular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:1679-84. 2006
    ..These findings require further validation from other large, randomized trials...
  31. ncbi request reprint Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
    E J Topol
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Lancet 354:2019-24. 1999
    ..We assessed in a randomised trial the long-term outcomes for potent adjunctive antiplatelet therapy given at the time of coronary stenting...
  32. ncbi request reprint Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 100:1977-82. 1999
    ..Diabetic patients in particular are a subgroup of patients with known underlying platelet abnormalities whose long-term response to abciximab has been shown to vary from that of nondiabetic patients...
  33. ncbi request reprint Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 103:1403-9. 2001
    ..The role of enhanced antiplatelet protection through pretreatment with the platelet ADP-receptor antagonist ticlopidine in preventing both the early and late complications of coronary stenting has not previously been explored...
  34. ncbi request reprint Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations
    Leslie Cho
    Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
    Am J Cardiol 91:1110-3. 2003
  35. ncbi request reprint Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition
    Leslie Cho
    Department of Cardiology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Am J Cardiol 91:742-3. 2003
  36. ncbi request reprint Direct thrombin inhibitors
    Michael S Chen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Curr Cardiol Rep 7:255-9. 2005
    ..Ongoing clinical trials will define the role of bivalirudin as an adjunct to primary PCI for ST-segment elevation myocardial infarction and in non-ST segment elevation acute coronary syndrome as an adjunct to an early invasive strategy...
  37. ncbi request reprint Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction
    P A Gum
    The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Int J Clin Pract 57:43-8. 2003
    ..In this article we review the major trials evaluating the use of abciximab in these clinical scenarios compared with placebo and alternative glycoprotein IIb/IIIa inhibitors...
  38. pmc Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis
    Inder M Singh
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Catheter Cardiovasc Interv 76:257-62. 2010
    ..We compared the long-term outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) for treatment of bare-metal in-stent restenosis (ISR)...
  39. ncbi request reprint Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Am Coll Cardiol 45:1932-8. 2005
    ..The objective of this study was to confirm that the efficacy and safety of percutaneous coronary intervention (PCI) in diabetic patients are not compromised by a bivalirudin-based antithrombotic strategy...
  40. ncbi request reprint GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary Arteries
    Arman T Askari
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 69:554-60. 2002
    ..However, subgroup analysis indicates that the combined regimen reduced the complications of acute MI, representing an important alternative strategy for pharmacologic reperfusion...
  41. ncbi request reprint Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model
    Zhongmin Zhou
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arterioscler Thromb Vasc Biol 22:1598-603. 2002
    ....
  42. ncbi request reprint Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials
    James C Blankenship
    Department of Cardiology, Geisinger Medical Center, Danville, Pennsylvania 17822, USA
    Catheter Cardiovasc Interv 57:476-83. 2002
    ....
  43. ncbi request reprint Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury
    Zhongmin Zhou
    Experimental Interventional Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 107:2238-43. 2003
    ..However, the role of RAGE/ligand interaction in neointimal hyperplasia after vascular injury remains unclear...
  44. pmc Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
    H S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Heart 89:1200-4. 2003
    ..An increase in the white blood cell (WBC) count is a non-specific response to inflammation. We hypothesised that a raised baseline WBC count would be a predictor of mortality in patients undergoing PCI...
  45. doi request reprint Strategies for the development of new PPAR agonists in diabetes
    Matthew A Cavender
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Eur J Cardiovasc Prev Rehabil 17:S32-7. 2010
    ..Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed...
  46. ncbi request reprint Should patients on long-term warfarin take aspirin for heart disease?
    Surabhi Madhwal
    Medicine Institute, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 75:206-8. 2008
  47. ncbi request reprint Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report
    Taral N Patel
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Invasive Cardiol 18:E211-3. 2006
    ..Moreover, while sufficient data are lacking, the combination of aspirin and cilostazol in this setting may provide adequate antithrombotic protection long term after drug-eluting stent placement...
  48. ncbi request reprint Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization
    A M Lincoff
    Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 82:36P-42P. 1998
    ..Excessive bleeding risk associated with these agents may be markedly diminished without loss of efficacy by reduction in conjunctive heparin dosing...
  49. ncbi request reprint Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus
    S H Park
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195-5066, USA
    Circulation 104:815-9. 2001
    ..The obese Zucker rat model may be an ideal diabetic model to further characterize the diabetic vascular response to injury...
  50. ncbi request reprint Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
    H D Aronow
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Lancet 357:1063-8. 2001
    ..67 [0.48-0.95], p=0.023). INTERPRETATION: Prescription of a lipid-lowering drug at hospital discharge was independently associated with reduced short-term mortality among patients after an acute coronary syndrome...
  51. doi request reprint Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195 0002, USA
    JACC Cardiovasc Interv 2:329-36. 2009
    ..Our aim was to assess the incidence of all-cause mortality in patients with anemia undergoing percutaneous coronary intervention (PCI) receiving drug-eluting stents (DES) or bare-metal stents (BMS)...
  52. ncbi request reprint Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model
    Kai Wang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA
    J Pharmacol Exp Ther 317:37-43. 2006
    ....
  53. doi request reprint Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 299:1561-73. 2008
    ..Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers...
  54. ncbi request reprint Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model
    Kai Wang
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Cardiovasc Pharmacol 45:61-7. 2005
    ..We conclude that celecoxib decreases the inflammatory response and intimal hyperplasia following vascular injury, possibly through inhibition of MCP-1 expression, implying a pivotal role of inflammation in the pathogenesis of restenosis...
  55. doi request reprint Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
    Matthew C Becker
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Am Heart J 157:606-12. 2009
    ..Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs). However, the relative cardiovascular safety of these therapies remains uncertain...
  56. doi request reprint Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA
    JAMA 299:1547-60. 2008
    ..Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease...
  57. ncbi request reprint Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury
    Kai Wang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Arterioscler Thromb Vasc Biol 25:1584-9. 2005
    ..This study was designed to determine whether P-selectin expression on platelet, endothelial, or both surfaces is critical to the inflammatory response and neointimal formation after arterial injury...
  58. ncbi request reprint The role of clopidogrel in the management of ischemic heart disease
    John M Galla
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Curr Opin Cardiol 22:273-9. 2007
    ..Platelet inhibition remains a key component in the prevention and treatment of ischemic heart disease. This review documents recent advances in the use of clopidogrel for the management of myocardial ischemia...
  59. ncbi request reprint Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study
    Nicholas G Smedira
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Cardiovasc Surg 131:686-92. 2006
    ..This trial was performed to evaluate the safety and efficacy of bivalirudin in off-pump coronary artery bypass grafting...
  60. doi request reprint Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites
    Gian M Novaro
    Department of Cardiology, Cleveland Clinic Florida, Weston, Florida, USA
    Am J Cardiol 101:506-9. 2008
    ..Further study is needed to investigate the mechanisms and potential genetic underpinnings behind this association...
  61. doi request reprint Magnitude and consequences of missing the acute infarct-related circumflex artery
    Amar Krishnaswamy
    Cleveland Clinic Division of Cardiovascular Medicine, OH 44195, USA
    Am Heart J 158:706-12. 2009
    ..Heightened awareness of this clinical scenario and the available methods to avoid missing this elusive diagnosis are imperative in our quest to further improve the outcomes of patients with acute myocardial infarction...
  62. ncbi request reprint Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes
    Deepak L Bhatt
    Department of Cardiovascular Medicine Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 92:136-40. 2003
    ..This finding supports a pivotal role for inflammation in acute coronary syndromes. Importantly, this study suggests that in-hospital revascularization may mitigate some of the excess risk due to inflammation...
  63. ncbi request reprint Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model
    Kai Wang
    Experimental Animal Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Ohio 44195, USA
    Mol Ther 7:597-603. 2003
    ..68 mm(2), P < 0.05). We concluded that efficient intramural adenovirus-mediated iNOS transfer can be achieved by using Infiltrator catheters. iNOS gene transfer significantly reduces neointimal hyperplasia following stent injury...
  64. ncbi request reprint Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox)
    Hitinder S Gurm
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 90:42-5. 2002
  65. ncbi request reprint Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model
    Kai Wang
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Arterioscler Thromb Vasc Biol 23:357-62. 2003
    ..We assessed the influence of a selective P2Y(12)-receptor antagonist (AR-C69931MX), in conjunction with thrombolytic therapy, on the prevention of platelet aggregation and thrombus formation...
  66. ncbi request reprint Management of acute coronary syndromes with emphasis on new information for the treatment of ST-segment elevation acute myocardial infarction
    A Michael Lincoff
    Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 14:1A-2A. 2002
  67. ncbi request reprint The GUSTO-V clinical trial
    A Michael Lincoff
    Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 14:21A-30A. 2002
  68. ncbi request reprint Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:20-5. 2003
    ..This study was designed to assess whether use of enoxaparin during percutaneous coronary intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to background therapy with eptifibatide...
  69. ncbi request reprint Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting
    Stephen G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:937-40. 2002
    ..06, p = 0.33), which is consistent with the results of prior randomized trials. ACE inhibitors appear to decrease late revascularization, possibly due to a reduction in restenosis after coronary stenting...
  70. ncbi request reprint Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
    Allen Jeremias
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:1209-11. 2002
  71. ncbi request reprint Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion
    Kai Wang
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Thromb Haemost 88:149-54. 2002
    ..Thus, administration of rPSGL-Ig decreases myocardial injury and inflammatory response for at least 7 days after reperfusion of ischemic myocardium...
  72. ncbi request reprint The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am Heart J 150:89-93. 2005
    ....
  73. ncbi request reprint Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus
    Matthew A Cavender
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiovasc Drugs 10:209-16. 2010
    ..If ongoing studies confirm the theoretical benefit and safety of dual PPAR-α/γ agonism, aleglitazar may become the first therapy demonstrated to reduce macrovascular complications in patients with diabetes...
  74. ncbi request reprint Impact of female sex on outcome after percutaneous coronary intervention
    John H Chiu
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:998-1002. 2004
    ..Prior reports have suggested that women have increased mortality compared to men following percutaneous coronary intervention (PCI). It remains unclear if this difference is secondary to sex or other confounding variables...
  75. ncbi request reprint Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 63:135-40. 2004
    ..Conversely, if the benefits of DESs are attenuated in routine practice, many groups of patients treated with BMSs may have nearly comparable results...
  76. doi request reprint Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk
    Lawrence D Lazar
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cleve Clin J Med 76:707-14. 2009
    ..However, bleeding complications were more frequent with prasugrel, and so this drug should be avoided in patients at higher risk of bleeding...
  77. ncbi request reprint Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 110:994-8. 2004
    ..Despite significant pharmacological and mechanical advancements in PCI, uncertainty remains about the optimal activated clotting time (ACT) for prevention of ischemic or hemorrhagic complications...
  78. ncbi request reprint Bivalirudin in PCI: an overview of the REPLACE-2 trial
    Anjli Maroo
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Semin Thromb Hemost 30:329-36. 2004
    ....
  79. ncbi request reprint Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
    Eric J Topol
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Med 113:1-6. 2002
    ..Brief intervention with this monoclonal antibody during percutaneous coronary revascularization is associated with significant improvement of long-term survival...
  80. ncbi request reprint Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality
    Vivek Rajagopal
    The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:190-2. 2004
    ....
  81. ncbi request reprint Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes
    J E Exaire
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Thromb Haemost 2:7-9. 2004
  82. ncbi request reprint Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model
    K Wang
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 38:577-82. 2001
    ....
  83. ncbi request reprint Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model
    Jung Han Yoon
    Department of Cardiology, F25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195 5066, USA
    Yonsei Med J 43:242-51. 2002
    ....
  84. ncbi request reprint Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial
    Frederick Feit
    Department of Medicine, New York University School of Medicine, New York, NY, USA
    Am J Cardiol 100:1364-9. 2007
    ..A number of baseline and periprocedural factors independently predicted major hemorrhage, including treatment with heparin plus GPI...
  85. ncbi request reprint Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies
    Cornelius M Dyke
    Department of Cardiovascular and Thoracic Surgery, Gaston Memorial Hospital, Gastonia, North Carolina 28054, USA
    Ann Thorac Surg 84:836-9. 2007
    ....
  86. ncbi request reprint Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis)
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 99:1687-90. 2007
    ....
  87. ncbi request reprint Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    JAMA 298:2497-506. 2007
    ....
  88. ncbi request reprint Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Lancet 369:907-19. 2007
    ..The aim of this study was to assess anticoagulation with the direct thrombin inhibitor bivalirudin during percutaneous coronary intervention in individuals with moderate and high-risk acute coronary syndromes...
  89. doi request reprint Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgen
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Coll Cardiol 51:1734-41. 2008
    ..The aim of this study was to compare outcomes in patients receiving consistent unfractionated heparin (UFH)/enoxaparin (ENOX) therapy and in those switched at randomization to bivalirudin monotherapy...
  90. ncbi request reprint Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Robert A Harrington
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Chest 133:670S-707S. 2008
    ..In low- to moderate-risk patients with NSTE ACS undergoing PCI, we recommend either bivalirudin with provisional ("bail-out") GP IIb/IIIa inhibitors or UFH plus a GP IIb/IIIa inhibitor over alternative antithrombotic regimens (Grade 1B)...
  91. doi request reprint Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Tria
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Coll Cardiol 52:807-14. 2008
    ..This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)...
  92. ncbi request reprint Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V
    Harmony R Reynolds
    Cardiovascular Clinical Research Center, New York University School of Medicine, New York, USA
    Arch Intern Med 167:2054-60. 2007
    ..Use of diagnostic and therapeutic modalities may also differ. There is controversy regarding whether female sex is an independent risk factor for death and/or bleeding...
  93. ncbi request reprint Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention
    Michele D Voeltz
    Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA
    Am J Cardiol 99:1513-7. 2007
    ....
  94. ncbi request reprint Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)
    Derek P Chew
    Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia
    Am J Cardiol 95:581-5. 2005
    ..The safety and efficacy of bivalirudin compared with heparin and planned glycoprotein IIb/IIIa inhibition in this high-risk group are comparable and consistent with the results of the overall trial...
  95. ncbi request reprint Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited
    W H Wilson Tang
    Circulation 110:3618-20. 2004
  96. ncbi request reprint Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 148:764-75. 2004
    ..Pilot trials suggest that the thrombin-specific anticoagulant bivalirudin may improve clinical outcomes in ACS...
  97. ncbi request reprint Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial
    David J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:1792-800. 2004
    ..The purpose of this study was to compare the cost of percutaneous coronary intervention (PCI) using bivalirudin with provisional platelet glycoprotein (GP) IIb/IIIa inhibition with that of heparin + routine GP IIb/IIIa inhibition...
  98. ncbi request reprint ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy)
    Fernando A Cura
    Department of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
    Am J Cardiol 94:859-63. 2004
    ..Patients with >70% ST-segment resolution within 60 minutes had markedly decreased mortality rates, irrespective of treatment...
  99. ncbi request reprint Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
    John L Petersen
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:269-76. 2004
    ..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
  100. ncbi request reprint Coupling drug and catheter therapy for myocardial infarction
    A Michael Lincoff
    JAMA 291:1000-2. 2004
  101. ncbi request reprint Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes
    John H Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Med 115:613-9. 2003
    ..To investigate the prognostic importance of new small Q waves following an acute coronary syndrome...